{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:51:10Z","timestamp":1792036270321,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.msard.2025.106547","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T18:41:34Z","timestamp":1748112094000},"page":"106547","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Real-world evidence from T\u00fcrkiye on cancer risk and treatment exposure in multiple sclerosis: A histopathology-verified, registry-based study"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9925","authenticated-orcid":false,"given":"Bilgin","family":"\u00d6zt\u00fcrk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Ta\u015fk\u0131ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa Murat","family":"Arat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aksel","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim","family":"Ata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015euayip","family":"Birinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"K\u00fcrt\u00fcnc\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106547_bib0027","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/ana.25701","article-title":"Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients","volume":"87","author":"Alping","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106547_bib0021","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/ene.15226","article-title":"Incidence and risk of cancer among multiple sclerosis patients: a matched population-based cohort study","volume":"29","author":"Bosco-L\u00e9vy","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106547_bib0013","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fneur.2019.00337","article-title":"Cancer risk and multiple sclerosis: evidence from a large italian cohort","volume":"10","author":"D'Amico","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106547_bib0014","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.msard.2014.05.005","article-title":"First-dose effects of fingolimod: pooled safety data from three phase 3 studies","volume":"3","author":"DiMarco","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106547_bib0008","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s13311-021-01073-y","article-title":"Association between disease-modifying therapies prescribed to persons with multiple sclerosis and cancer: a WHO pharmacovigilance database analysis","volume":"18","author":"Dolladille","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2025.106547_bib0001","first-page":"172","article-title":"Cancer risk among patients with multiple sclerosis: a cohort study in Isfahan","volume":"8","author":"Etemadifar","year":"2017","journal-title":"Iran. Caspian J. Int. Med."},{"key":"10.1016\/j.msard.2025.106547_bib0002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jns.2016.09.005","article-title":"Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk","volume":"370","author":"Gaindh","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106547_bib0003","article-title":"Risk of cancer in multiple sclerosis (MS): a systematic review and meta-analysis","volume":"19","author":"Ghajarzadeh","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2025.106547_bib0030","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s00415-024-12882-4","article-title":"Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs): a systematic review and meta-analysis","volume":"272","author":"Giannopapas","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106547_bib0024","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-91912-x","article-title":"Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients","volume":"11","author":"Gil-Bernal","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2025.106547_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105091","article-title":"Cancer risk, disease-modifying therapy, and age in multiple sclerosis: a retrospective population-based cohort study","volume":"80","author":"Greenfield","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2025.106547_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103209","article-title":"Incidence of cancer in multiple sclerosis before and after the treatment era- a registry- based cohort study","volume":"55","author":"Grytten","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106547_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165027","article-title":"Risk of premenopausal and postmenopausal breast cancer among multiple sclerosis patients","volume":"11","author":"Hajiebrahimi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2025.106547_bib0005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.msard.2019.08.005","article-title":"Risk of cancer among Finnish multiple sclerosis patients","volume":"35","author":"Hongell","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106547_bib0010","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40263-018-0564-y","article-title":"Cancer risk in patients with multiple sclerosis: potential impact of disease-modifying drugs","volume":"32","author":"Lebrun","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2025.106547_bib0028","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00415-011-5929-9","article-title":"Cancer and multiple sclerosis in the era of disease-modifying treatments","volume":"258","author":"Lebrun","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106547_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103679","article-title":"Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: a population-based study on Tuscan residents","volume":"60","author":"Mariottini","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106547_bib0020","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/1352458514564489","article-title":"A systematic review of the incidence and prevalence of cancer in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106547_bib0019","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1212\/WNL.0000000000011219","article-title":"Cancer incidence and mortality rates in multiple sclerosis: a matched cohort study","volume":"96","author":"Marrie","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106547_bib0018","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","article-title":"Current cancer epidemiology","volume":"9","author":"Mattiuzzi","year":"2019","journal-title":"J. Epidemiol. Glob. Health."},{"key":"10.1016\/j.msard.2025.106547_bib0026","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.3389\/fimmu.2019.02954","article-title":"Multiple sclerosis and cancer: the ying-yang effect of disease modifying therapies","volume":"10","author":"Melamed","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106547_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188120","article-title":"Decreased prevalence of cancer in patients with multiple sclerosis: a case-control study","volume":"12","author":"Moisset","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2025.106547_bib0023","first-page":"114","article-title":"The prevalence of cancer in patients with multiple sclerosis (MS) who were under treatment with natalizumab (Tysabri): a systematic review and meta-analysis","volume":"14","author":"Nasirzadeh","year":"2023","journal-title":"Int. J. Prev. Med."},{"key":"10.1016\/j.msard.2025.106547_bib0015","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1177\/13524585241245318","article-title":"Prevalence and incidence of multiple sclerosis in Turkey: a nationwide epidemiologic study","volume":"30","author":"\u00d6zt\u00fcrk","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106547_bib0029","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209885","article-title":"Cancer risk among patients with multiple sclerosis: a 10-year nationwide retrospective cohort study","volume":"103","author":"Pierret","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106547_bib0012","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12883-017-0932-0","article-title":"Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study","volume":"17","author":"Ragonese","year":"2017","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2025.106547_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158192","article-title":"Therapeutic potential of fingolimod and dimethyl fumarate in non-small cell lung cancer preclinical models","author":"Rupp","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2025.106547_bib0007","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/ene.12267","article-title":"Increased breast cancer risk for patients with multiple sclerosis: a nationwide population-based cohort study","volume":"21","author":"Sun","year":"2014","journal-title":"Eur. J. Neurol."}],"updated-by":[{"DOI":"10.1016\/j.msard.2025.106660","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000}}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825002895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825002895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T23:10:40Z","timestamp":1754003440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825002895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":28,"alternative-id":["S2211034825002895"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106547","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evidence from T\u00fcrkiye on cancer risk and treatment exposure in multiple sclerosis: A histopathology-verified, registry-based study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106547","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106547"}}